Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
Real-world outcomes in patients with relapsed-refractory multiple myeloma (RRMM) with prior proteasome inhibitor and lenalidomide exposure in Sweden
Vincent Luong, MD (he/him/his)
Resident, PhD student
Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institutet and Department of Hematology, Karolinska University Hospital, Sweden
Stockholm, Stockholms Lan, Sweden